Press Release
January 16, 2024

Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential

The Life Sciences team represented Myrobalan Therapeutics in its $24 million Series A financing. The round was led by Co-win Ventures, with participation from new and existing investors including, Guan Zi Equity Investment (Li Shui) Partnership (Limited Partnership), 3E Bioventures Capital, and AB Magnitude Ventures Group.

Myrobalan Therapeutics is a biotechnology company headquartered in Medford, Massachusetts, with a focus on developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and central nervous system conditions.

Co-win Ventures is an angel and early-stage investor in technology, media, telecommunications and healthcare. Its funds include seed funds, venture capital funds and private equity funds.

The Goodwin team was led by Can Cui and Steven Green and included Claire Zhang, Grace Wirth, Andy Barton, and Julie K. Tibbets, with support from Jennifer Webb, David Elcino Lopes, Flip Schmidt, and William Rixmann.

For more details, read the press release and articles in Endpoint and BioSpace.